Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at June 30, 2010:

• 108,104 shares of Innate Pharma, and
• 51,728.95 euros in cash.

For information, the following assets appeared on the liquidity account at the latest report:

• 69,741 shares of Innate Pharma, and
• 121,955.05 euros in cash.